{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:15:14Z","timestamp":1788311714293,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000887","name":"Huntington's Disease Society of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2017-00915"],"award-info":[{"award-number":["2017-00915"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-00732"],"award-info":[{"award-number":["2022-00732"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["ALFGBG-715986"],"award-info":[{"award-number":["ALFGBG-715986"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["ALFGBG-965240"],"award-info":[{"award-number":["ALFGBG-965240"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2023-00356"],"award-info":[{"award-number":["2023-00356"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-01018"],"award-info":[{"award-number":["2022-01018"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-02397"],"award-info":[{"award-number":["2019-02397"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["ALFGBG-71320"],"award-info":[{"award-number":["ALFGBG-71320"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF-930351"],"award-info":[{"award-number":["AF-930351"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF-939721"],"award-info":[{"award-number":["AF-939721"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF-968270"],"award-info":[{"award-number":["AF-968270"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2017-0243"],"award-info":[{"award-number":["FO2017-0243"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["ALZ2022-0006"],"award-info":[{"award-number":["ALZ2022-0006"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2022-0270"],"award-info":[{"award-number":["FO2022-0270"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["JPND2019-466-236"],"award-info":[{"award-number":["JPND2019-466-236"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["JPND2021-00694"],"award-info":[{"award-number":["JPND2021-00694"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ZEN-21-848495"],"award-info":[{"award-number":["ZEN-21-848495"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["SG-23-1038904 QC"],"award-info":[{"award-number":["SG-23-1038904 QC"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-21-831376-C"],"award-info":[{"award-number":["ADSF-21-831376-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-21-831381-C"],"award-info":[{"award-number":["ADSF-21-831381-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-21-831377-C"],"award-info":[{"award-number":["ADSF-21-831377-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-24-1284328-C"],"award-info":[{"award-number":["ADSF-24-1284328-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union\u2019s Horizon Europe research and innovation programme","award":["101053962"],"award-info":[{"award-number":["101053962"]}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["201809-2016862"],"award-info":[{"award-number":["201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019599","name":"European Partnership on Metrology","doi-asserted-by":"publisher","award":["#22HLT07"],"award-info":[{"award-number":["#22HLT07"]}],"id":[{"id":"10.13039\/100019599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["860197"],"award-info":[{"award-number":["860197"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","award":["UKDRI-1003"],"award-info":[{"award-number":["UKDRI-1003"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Tau is a microtubule protein that is known to be hyperphosphorylated and to aggregate in several chronic neurodegenerative disorders. In many cases, in particular in Alzheimer\u2019s disease, the degree of tau pathology has been demonstrated to correlate with cognitive deficits and\/or decline. In Huntington\u2019s disease (HD), a dominantly inherited neurodegenerative disorder, both cognitive impairments and abnormal tau expression have been reported to occur, along with the accumulation of the mutant huntingtin protein. In this respect, tau has been shown to be present in the cerebrospinal fluid of individuals with HD and to increase with disease progression. However, how this relates to changes in tau found in the periphery is largely unknown. In this study, we collected blood samples from patients with HD and isolated multiple blood components including plasma, platelets, and peripheral blood mononuclear cells to measure their tau levels and subsequently correlate these to cognitive impairments and disease stage. Our results suggest that the amount of tau, particularly N-terminal tau (NTA-tau) and total tau (t-tau), is elevated\u00a0in all assayed blood components and that the quantity of tau within platelets, specifically, is strongly correlated with disease severity.<\/jats:p>","DOI":"10.1007\/s00415-025-12966-9","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T13:17:22Z","timestamp":1741267042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tau levels in platelets isolated from Huntington\u2019s disease patients serve as a biomarker of disease severity"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2782-5454","authenticated-orcid":false,"given":"Melanie","family":"Alpaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lantero-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uriel","family":"Manseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Maiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena L.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Masnata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaline V.","family":"Fazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chouinard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Labib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"12966_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/B978-0-323-98817-9.00015-6","volume":"196","author":"G Devi","year":"2023","unstructured":"Devi G (2023) The tauopathies. Handb Clin Neurol 196:251\u2013265. https:\/\/doi.org\/10.1016\/B978-0-323-98817-9.00015-6","journal-title":"Handb Clin Neurol"},{"key":"12966_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/brain\/awx365","volume":"141","author":"M Albert","year":"2018","unstructured":"Albert M, Zhu Y, Moghekar A et al (2018) Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years. Brain 141:877\u2013887. https:\/\/doi.org\/10.1093\/brain\/awx365","journal-title":"Brain"},{"key":"12966_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.parkreldis.2014.12.027","volume":"21","author":"C Liu","year":"2015","unstructured":"Liu C, Cholerton B, Shi M et al (2015) CSF tau and tau\/A\u03b242 predict cognitive decline in Parkinson\u2019s disease. Parkinsonism Relat Disord 21:271\u2013276. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.12.027","journal-title":"Parkinsonism Relat Disord"},{"key":"12966_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/sj.mp.4001220","volume":"8","author":"M Riemenschneider","year":"2003","unstructured":"Riemenschneider M, Wagenpfeil S, Vanderstichele H et al (2003) Phospho-tau\/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 8:343\u2013347. https:\/\/doi.org\/10.1038\/sj.mp.4001220","journal-title":"Mol Psychiatry"},{"key":"12966_CR5","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/brain\/awv107","volume":"138","author":"R Vuono","year":"2015","unstructured":"Vuono R, Winder-Rhodes S, de Silva R et al (2015) The role of tau in the pathological process and clinical expression of Huntington\u2019s disease. Brain 138:1907\u20131918. https:\/\/doi.org\/10.1093\/brain\/awv107","journal-title":"Brain"},{"key":"12966_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3233\/JHD-230588","volume":"12","author":"T Petrozziello","year":"2023","unstructured":"Petrozziello T, Huntress SS, Castillo-Torres AL et al (2023) Age-Dependent Increase in Tau Phosphorylation at Serine 396 in Huntington\u2019s Disease Prefrontal Cortex. J Huntingtons Dis 12:267\u2013281. https:\/\/doi.org\/10.3233\/JHD-230588","journal-title":"J Huntingtons Dis"},{"key":"12966_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3389\/fncel.2019.00574","volume":"13","author":"M Fern\u00e1ndez-Nogales","year":"2019","unstructured":"Fern\u00e1ndez-Nogales M, Lucas JJ (2019) Altered levels and isoforms of tau and nuclear membrane invaginations in huntington\u2019s disease. Front Cell Neurosci 13:574. https:\/\/doi.org\/10.3389\/fncel.2019.00574","journal-title":"Front Cell Neurosci"},{"key":"12966_CR8","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/brain\/awx255","volume":"140","author":"G Cisbani","year":"2017","unstructured":"Cisbani G, Maxan A, Kordower JH et al (2017) Presence of tau pathology within foetal neural allografts in patients with Huntington\u2019s and Parkinson\u2019s disease. Brain 140:2982\u20132992. https:\/\/doi.org\/10.1093\/brain\/awx255","journal-title":"Brain"},{"key":"12966_CR9","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/jnnp.48.6.530","volume":"48","author":"RH Myers","year":"1985","unstructured":"Myers RH, Sax DS, Schoenfeld M et al (1985) Late onset of Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 48:530\u2013534. https:\/\/doi.org\/10.1136\/jnnp.48.6.530","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12966_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1212\/wnl.35.2.273","volume":"35","author":"MG Reyes","year":"1985","unstructured":"Reyes MG, Gibbons S (1985) Dementia of the Alzheimer\u2019s type and Huntington\u2019s disease. Neurology 35:273\u2013277. https:\/\/doi.org\/10.1212\/wnl.35.2.273","journal-title":"Neurology"},{"key":"12966_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ana.410030616","volume":"3","author":"GC McIntosh","year":"1978","unstructured":"McIntosh GC, Jameson HD, Markesbery WR (1978) Huntington disease associated with Alzheimer disease. Ann Neurol 3:545\u2013548. https:\/\/doi.org\/10.1002\/ana.410030616","journal-title":"Ann Neurol"},{"key":"12966_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172762","volume":"12","author":"V Niemel\u00e4","year":"2017","unstructured":"Niemel\u00e4 V, Landtblom A-M, Blennow K, Sundblom J (2017) Tau or neurofilament light\u2014Which is the more suitable biomarker for Huntington\u2019s disease? PLoS ONE 12:e0172762. https:\/\/doi.org\/10.1371\/journal.pone.0172762","journal-title":"PLoS ONE"},{"key":"12966_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jnc.13719","volume":"139","author":"FB Rodrigues","year":"2016","unstructured":"Rodrigues FB, Byrne L, McColgan P et al (2016) Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington\u2019s disease. J Neurochem 139:22\u201325. https:\/\/doi.org\/10.1111\/jnc.13719","journal-title":"J Neurochem"},{"key":"12966_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52031","author":"S Martinez-Horta","year":"2024","unstructured":"Martinez-Horta S, Perez-Perez J, Perez-Gonzalez R et al (2024) Cognitive phenotype and neurodegeneration associated with Tau in Huntington\u2019s disease. Annal Clin Translat Neurol. https:\/\/doi.org\/10.1002\/acn3.52031","journal-title":"Annal Clin Translat Neurol"},{"key":"12966_CR15","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.parkreldis.2011.06.010","volume":"17","author":"R Constantinescu","year":"2011","unstructured":"Constantinescu R, Romer M, Zetterberg H et al (2011) Increased levels of total tau protein in the cerebrospinal fluid in Huntington\u2019s disease. Parkinsonism Relat Disord 17:714\u2013715. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.06.010","journal-title":"Parkinsonism Relat Disord"},{"key":"12966_CR16","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.ymthe.2022.01.020","volume":"30","author":"M Alpaugh","year":"2022","unstructured":"Alpaugh M, Masnata M, de Rus JA et al (2022) Passive immunization against phosphorylated tau improves features of Huntington\u2019s disease pathology. Mol Ther 30:1500\u20131522. https:\/\/doi.org\/10.1016\/j.ymthe.2022.01.020","journal-title":"Mol Ther"},{"key":"12966_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nm.3617","volume":"20","author":"M Fern\u00e1ndez-Nogales","year":"2014","unstructured":"Fern\u00e1ndez-Nogales M, Cabrera JR, Santos-Galindo M et al (2014) Huntington\u2019s disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 20:881\u2013885. https:\/\/doi.org\/10.1038\/nm.3617","journal-title":"Nat Med"},{"key":"12966_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK et al (2021) Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol 141:709\u2013724. https:\/\/doi.org\/10.1007\/s00401-021-02275-6","journal-title":"Acta Neuropathol"},{"key":"12966_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"J Lantero Rodriguez","year":"2020","unstructured":"Lantero Rodriguez J, Karikari TK, Su\u00e1rez-Calvet M et al (2020) Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol 140:267\u2013278. https:\/\/doi.org\/10.1007\/s00401-020-02195-x","journal-title":"Acta Neuropathol"},{"key":"12966_CR20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT et al (2020) Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324:772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134","journal-title":"JAMA"},{"key":"12966_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13024-024-00707-x","volume":"19","author":"J Lantero-Rodriguez","year":"2024","unstructured":"Lantero-Rodriguez J, Salvad\u00f3 G, Snellman A et al (2024) Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer\u2019s Disease. Mol Neurodegener 19:19. https:\/\/doi.org\/10.1186\/s13024-024-00707-x","journal-title":"Mol Neurodegener"},{"key":"12966_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med 284:643\u2013663. https:\/\/doi.org\/10.1111\/joim.12816","journal-title":"J Intern Med"},{"key":"12966_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","volume":"26","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Benedet AL, Ashton NJ et al (2021) Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s disease neuroimaging initiative. Mol Psychiatry 26:429\u2013442. https:\/\/doi.org\/10.1038\/s41380-020-00923-z","journal-title":"Mol Psychiatry"},{"key":"12966_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ et al (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19:422\u2013433. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5","journal-title":"Lancet Neurol"},{"key":"12966_CR25","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N et al (2022) Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med 28:2555\u20132562. https:\/\/doi.org\/10.1038\/s41591-022-02074-w","journal-title":"Nat Med"},{"key":"12966_CR26","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1002\/alz.13119","volume":"19","author":"J Lantero-Rodriguez","year":"2023","unstructured":"Lantero-Rodriguez J, Tissot C, Snellman A et al (2023) Plasma and CSF concentrations of N-terminal tau fragments associate with in vivo neurofibrillary tangle burden. Alzheimers Dement 19:5343\u20135354. https:\/\/doi.org\/10.1002\/alz.13119","journal-title":"Alzheimers Dement"},{"key":"12966_CR27","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3233\/JAD-180637","volume":"67","author":"L Guzm\u00e1n-Mart\u00ednez","year":"2019","unstructured":"Guzm\u00e1n-Mart\u00ednez L, Tapia JP, Far\u00edas GA et al (2019) The Alz-tau Biomarker for Alzheimer\u2019s Disease: Study in a Caucasian Population. Journal of Alzheimer\u2019s Disease 67:1181\u20131186. https:\/\/doi.org\/10.3233\/JAD-180637","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"12966_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.31083\/j.fbl2705153","volume":"27","author":"B Sarg","year":"2022","unstructured":"Sarg B, Korde DS, Marksteiner J, Humpel C (2022) Platelet TAU is associated with changes in depression and Alzheimer\u2019s disease. FBL 27:153. https:\/\/doi.org\/10.31083\/j.fbl2705153","journal-title":"FBL"},{"key":"12966_CR29","doi-asserted-by":"publisher","first-page":"800","DOI":"10.2174\/1567205015666180404165915","volume":"15","author":"EB Mukaetova-Ladinska","year":"2018","unstructured":"Mukaetova-Ladinska EB, Abdell-All Z, Andrade J et al (2018) Platelet tau protein as a potential peripheral biomarker in alzheimer\u2019s disease: an explorative study. Curr Alzheimer Res 15:800\u2013808. https:\/\/doi.org\/10.2174\/1567205015666180404165915","journal-title":"Curr Alzheimer Res"},{"key":"12966_CR30","first-page":"1085","volume":"6","author":"H Kim","year":"1991","unstructured":"Kim H, Strong TV, Anderson SJ (1991) Evidence for tau expression in cells of monocyte lineage and its in vitro phosphorylation by v-fms kinase. Oncogene 6:1085\u20131087","journal-title":"Oncogene"},{"key":"12966_CR31","doi-asserted-by":"publisher","first-page":"fcae030","DOI":"10.1093\/braincomms\/fcae030","volume":"6","author":"MK Bondulich","year":"2024","unstructured":"Bondulich MK, Phillips J, Ca\u00f1ibano-Pico M et al (2024) Translatable plasma and CSF biomarkers for use in mouse models of Huntington\u2019s disease. Brain Commun 6:fcae030. https:\/\/doi.org\/10.1093\/braincomms\/fcae030","journal-title":"Brain Commun"},{"key":"12966_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3233\/JHD-180291","volume":"7","author":"EB Diago","year":"2018","unstructured":"Diago EB, Mart\u00ednez-Horta S, Lasaosa SS et al (2018) Circadian Rhythm, Cognition, and Mood Disorders in Huntington\u2019s Disease. J Huntingtons Dis 7:193\u2013198. https:\/\/doi.org\/10.3233\/JHD-180291","journal-title":"J Huntingtons Dis"},{"key":"12966_CR33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1176\/appi.neuropsych.14100265","volume":"27","author":"M Dale","year":"2015","unstructured":"Dale M, van Duijn E (2015) Anxiety in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci 27:262\u2013271. https:\/\/doi.org\/10.1176\/appi.neuropsych.14100265","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"12966_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105166","volume":"149","author":"ML Clark","year":"2023","unstructured":"Clark ML, Abimanyi-Ochom J, Le H et al (2023) A systematic review and meta-analysis of depression and apathy frequency in adult-onset Huntington\u2019s disease. Neurosci Biobehav Rev 149:105166. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105166","journal-title":"Neurosci Biobehav Rev"},{"key":"12966_CR35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group (1996) Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov Disord 11:136\u2013142. https:\/\/doi.org\/10.1002\/mds.870110204","journal-title":"Mov Disord"},{"key":"12966_CR36","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.12502","volume":"4","author":"FB Rodrigues","year":"2017","unstructured":"Rodrigues FB, Abreu D, Dam\u00e1sio J et al (2017) Survival, mortality, causes and places of death in a European Huntington\u2019s disease prospective cohort. Mov Disord Clin Pract 4:737\u2013742. https:\/\/doi.org\/10.1002\/mdc3.12502","journal-title":"Mov Disord Clin Pract"},{"key":"12966_CR37","first-page":"116","volume":"59","author":"E Tukiainen","year":"1981","unstructured":"Tukiainen E, Wikstr\u00f6m J, Kilpel\u00e4inen H (1981) Uptake of 5-hydroxytryptamine by blood platelets in Huntington\u2019s chorea and Alzheimer type of presenile dementia. Med Biol 59:116\u2013120","journal-title":"Med Biol"},{"key":"12966_CR38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1212\/wnl.28.3.300","volume":"28","author":"GS Omenn","year":"1978","unstructured":"Omenn GS, Smith L (1978) Platelet uptake of serotonin and dopamine in Huntington disease. Neurology 28:300\u2013303. https:\/\/doi.org\/10.1212\/wnl.28.3.300","journal-title":"Neurology"},{"key":"12966_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1017\/s0317167100025130","volume":"4","author":"RF Butterworth","year":"1977","unstructured":"Butterworth RF, Gonce M, Barbeau A (1977) Platelet dopamine uptake in Huntington\u2019s chorea and Gilles de la Tourette\u2019s syndrome: effect of haloperidol. Can J Neurol Sci 4:285\u2013288. https:\/\/doi.org\/10.1017\/s0317167100025130","journal-title":"Can J Neurol Sci"},{"key":"12966_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00702-003-0103-x","volume":"111","author":"M Markianos","year":"2004","unstructured":"Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2004) Platelet monoamine oxidase activity in subjects tested for Huntington\u2019s disease gene mutation. J Neural Transm (Vienna) 111:475\u2013483. https:\/\/doi.org\/10.1007\/s00702-003-0103-x","journal-title":"J Neural Transm (Vienna)"},{"key":"12966_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1440-1681.1987.tb01511.x","volume":"14","author":"TR Norman","year":"1987","unstructured":"Norman TR, Chiu E, French MA (1987) Platelet monoamine oxidase activity in patients with Huntington\u2019s disease. Clin Exp Pharmacol Physiol 14:547\u2013550. https:\/\/doi.org\/10.1111\/j.1440-1681.1987.tb01511.x","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"12966_CR42","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1136\/jnnp.41.9.809","volume":"41","author":"J Mann","year":"1978","unstructured":"Mann J, Chiu E (1978) Platelet monoamine oxidase activity in Huntington\u2019s chorea. J Neurol Neurosurg Psychiatry 41:809\u2013812. https:\/\/doi.org\/10.1136\/jnnp.41.9.809","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12966_CR43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(77)91037-6","volume":"309","author":"DR Mclean","year":"1977","unstructured":"Mclean DR, Nihei T (1977) Uptake of dopamine and 5-Hydroxytryptamine by platelets from patients with Huntington\u2019s chorea. The Lancet 309:249\u2013250. https:\/\/doi.org\/10.1016\/S0140-6736(77)91037-6","journal-title":"The Lancet"},{"key":"12966_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1017\/s0317167100043110","volume":"8","author":"DR McLean","year":"1981","unstructured":"McLean DR, Nihei T (1981) Dopamine uptake capacity of platelets from people at risk for Huntington\u2019s chorea. Can J Neurol Sci 8:167\u2013168. https:\/\/doi.org\/10.1017\/s0317167100043110","journal-title":"Can J Neurol Sci"},{"key":"12966_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0140-6736(78)91554-4","volume":"2","author":"E Bonilla","year":"1978","unstructured":"Bonilla E, Vargas-Urribari N, Navas F (1978) Uptake of 14C-dopamine in platelets of Huntington\u2019s chorea patients and symptom-free offspring. Lancet 2:161\u2013162. https:\/\/doi.org\/10.1016\/s0140-6736(78)91554-4","journal-title":"Lancet"},{"key":"12966_CR46","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.3390\/ijms24076051","volume":"24","author":"E Morena","year":"2023","unstructured":"Morena E, Romano C, Marconi M et al (2023) Peripheral biomarkers in manifest and premanifest Huntington\u2019s disease. Int J Mol Sci 24:6051. https:\/\/doi.org\/10.3390\/ijms24076051","journal-title":"Int J Mol Sci"},{"key":"12966_CR47","first-page":"13","volume":"17","author":"J Wang","year":"2002","unstructured":"Wang J, Wang X, Liu R et al (2002) In vitro analysis of tau phosphorylation sites and its biological activity. Chin Med Sci J 17:13\u201316","journal-title":"Chin Med Sci J"},{"key":"12966_CR48","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1021\/bi051635j","volume":"45","author":"T Li","year":"2006","unstructured":"Li T, Hawkes C, Qureshi HY et al (2006) Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 45:3134\u20133145. https:\/\/doi.org\/10.1021\/bi051635j","journal-title":"Biochemistry"},{"key":"12966_CR49","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fncel.2018.00338","volume":"12","author":"AD Alonso","year":"2018","unstructured":"Alonso AD, Cohen LS, Corbo C et al (2018) Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability. Front Cell Neurosci 12:338. https:\/\/doi.org\/10.3389\/fncel.2018.00338","journal-title":"Front Cell Neurosci"},{"key":"12966_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1006\/abbi.1998.0813","volume":"357","author":"A Sengupta","year":"1998","unstructured":"Sengupta A, Kabat J, Novak M et al (1998) Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys 357:299\u2013309. https:\/\/doi.org\/10.1006\/abbi.1998.0813","journal-title":"Arch Biochem Biophys"},{"key":"12966_CR51","doi-asserted-by":"publisher","first-page":"15733","DOI":"10.1074\/jbc.M000389200","volume":"275","author":"T Maas","year":"2000","unstructured":"Maas T, Eidenm\u00fcller J, Brandt R (2000) Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem 275:15733\u201315740. https:\/\/doi.org\/10.1074\/jbc.M000389200","journal-title":"J Biol Chem"},{"key":"12966_CR52","doi-asserted-by":"publisher","first-page":"12916","DOI":"10.3390\/ijms252312916","volume":"25","author":"G Lombardi","year":"2024","unstructured":"Lombardi G, Pancani S, Manca R et al (2024) Role of blood P-Tau Isoforms (181, 217, 231) in predicting conversion from MCI to dementia due to Alzheimer\u2019s disease: a review and meta-analysis. Int J Mol Sci 25:12916. https:\/\/doi.org\/10.3390\/ijms252312916","journal-title":"Int J Mol Sci"},{"key":"12966_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-230799","volume":"98","author":"Z Li","year":"2024","unstructured":"Li Z, Fan Z, Zhang Q (2024) The associations of phosphorylated Tau 181 and Tau 231 Levels in plasma and cerebrospinal fluid with cognitive function in Alzheimer\u2019s disease: a systematic review and meta-analysis. J Alzheimers Dis 98:13\u201332. https:\/\/doi.org\/10.3233\/JAD-230799","journal-title":"J Alzheimers Dis"},{"key":"12966_CR54","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1007\/s00415-024-12669-7","volume":"271","author":"A Pilotto","year":"2024","unstructured":"Pilotto A, Ashton NJ, Lupini A et al (2024) Plasma NfL, GFAP, amyloid, and p-tau species as prognostic biomarkers in Parkinson\u2019s disease. J Neurol 271:7537\u20137546. https:\/\/doi.org\/10.1007\/s00415-024-12669-7","journal-title":"J Neurol"},{"key":"12966_CR55","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209418","volume":"102","author":"K Bolsewig","year":"2024","unstructured":"Bolsewig K, van Unnik AAJM, Blujdea ER et al (2024) Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies. Neurology 102:e209418. https:\/\/doi.org\/10.1212\/WNL.0000000000209418","journal-title":"Neurology"},{"key":"12966_CR56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/jnnp-2021-328623","volume":"93","author":"J Lagarde","year":"2022","unstructured":"Lagarde J, Olivieri P, Tonietto M et al (2022) Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 93:459\u2013467. https:\/\/doi.org\/10.1136\/jnnp-2021-328623","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12966_CR57","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.3390\/biomedicines11123336","volume":"11","author":"J Achenbach","year":"2023","unstructured":"Achenbach J, Stodt B, Saft C (2023) Factors influencing the total functional capacity score as a critical endpoint in Huntington\u2019s Disease research. Biomedicines 11:3336. https:\/\/doi.org\/10.3390\/biomedicines11123336","journal-title":"Biomedicines"},{"key":"12966_CR58","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/jnnp-2018-318854","volume":"90","author":"HL Denis","year":"2019","unstructured":"Denis HL, Lamontagne-Proulx J, St-Amour I et al (2019) Platelet abnormalities in Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 90:272\u2013283. https:\/\/doi.org\/10.1136\/jnnp-2018-318854","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12966_CR59","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.mito.2013.05.006","volume":"13","author":"AC Silva","year":"2013","unstructured":"Silva AC, Almeida S, La\u00e7o M et al (2013) Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington\u2019s disease carriers. Mitochondrion 13:801\u2013809. https:\/\/doi.org\/10.1016\/j.mito.2013.05.006","journal-title":"Mitochondrion"},{"key":"12966_CR60","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/ajmg.b.30223","volume":"139B","author":"V Maglione","year":"2005","unstructured":"Maglione V, Giallonardo P, Cannella M et al (2005) Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington\u2019s disease. Am J Med Genet B Neuropsychiatr Genet 139B:101\u2013105. https:\/\/doi.org\/10.1002\/ajmg.b.30223","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"12966_CR61","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neulet.2005.09.037","volume":"393","author":"V Maglione","year":"2006","unstructured":"Maglione V, Cannella M, Martino T et al (2006) The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington\u2019s disease patients with predominant chorea. Neurosci Lett 393:27\u201330. https:\/\/doi.org\/10.1016\/j.neulet.2005.09.037","journal-title":"Neurosci Lett"},{"key":"12966_CR62","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1096\/fj.03-0079fje","volume":"17","author":"K Varani","year":"2003","unstructured":"Varani K, Abbracchio MP, Cannella M et al (2003) Aberrant A2A receptor function in peripheral blood cells in Huntington\u2019s disease. FASEB J 17:2148\u20132150. https:\/\/doi.org\/10.1096\/fj.03-0079fje","journal-title":"FASEB J"},{"key":"12966_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089745","volume":"9","author":"A Carrizzo","year":"2014","unstructured":"Carrizzo A, Di Pardo A, Maglione V et al (2014) Nitric oxide dysregulation in platelets from patients with advanced huntington disease. PLoS ONE 9:e89745. https:\/\/doi.org\/10.1371\/journal.pone.0089745","journal-title":"PLoS ONE"},{"key":"12966_CR64","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3233\/JAD-160652","volume":"55","author":"A Slachevsky","year":"2017","unstructured":"Slachevsky A, Guzm\u00e1n-Mart\u00ednez L, Delgado C et al (2017) Tau platelets correlate with regional brain atrophy in patients with Alzheimer\u2019s disease. Journal of Alzheimer\u2019s Disease 55:1595\u20131603. https:\/\/doi.org\/10.3233\/JAD-160652","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"12966_CR65","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/gerona\/glz005","volume":"75","author":"Y Shi","year":"2020","unstructured":"Shi Y, Gu L, Wang Q et al (2020) Platelet Amyloid-\u03b2 protein precursor (A\u0392PP) ratio and phosphorylated tau as promising indicators for early alzheimer\u2019s disease. J Gerontol Ser A 75:664\u2013670. https:\/\/doi.org\/10.1093\/gerona\/glz005","journal-title":"J Gerontol Ser A"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12966-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-12966-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12966-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T17:40:17Z","timestamp":1742233217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-12966-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["12966"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-12966-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The other authors declare that they have no conflict of interest. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). FC is a co-founder of Synucure Therapeutics and a consultant for Axoltis and HD immune Vienna. RAB is on the editorial board of the Journal of Neurology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"254"}}